Diplomat named exclusive distributor for Taro’s Keveyis

FLINT, Mich. – Diplomat Pharmacy has been named the exclusive distributor for Taro’s primary hyperkalemic and hypokalemic periodic paralysis treatment, Keveyis (dichlorphenamide), the company announced Thursday.

 

Keveyis was recently approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.

 

“We are excited to be a sole distributor of Keveyis and give patients a therapy option for primary hyperkalemic and hypokalemic periodic paralysis,” said Gary Kadlec, president of Diplomat. “The FDA approval of Keveyis is an important advancement in the treatment of hyperkalemic and hypokalemic periodic paralysis, and we are proud to be able to support these patients and their caregivers.”

 

Taro has created the Keys2Care program, which will provide a suite of patient support services to ensure people diagnosed with periodic paralysis can receive treatment with Keveyis as soon as possible. As part of this program, Diplomat is working with Taro to offer access and support to patients who are prescribed Keveyis and their caregivers.

 

Keveyis is expected to be available in the third quarter.